All articles tagged with #ucb
UCB agreed to acquire Neurona Therapeutics for $650 million in cash plus up to $500 million in milestones, expanding into regenerative medicine with Neurona's NRTX-1001 neuronal cell therapy in phase I/II trials for drug-resistant mesial temporal lobe epilepsy, with closing expected by quarter's end.
UCB to acquire Neurona Therapeutics for up to $1.15 billion ($650 million upfront plus up to $500 million in milestones), adding NRTX-1001, a regenerative neural cell therapy in Phase I/II for drug-resistant mesial temporal lobe epilepsy that aims to restore neural circuitry by delivering GABA-producing cells. The deal underscores UCB’s push into regenerative medicine, with RMAT/PRIME designations reflecting regulatory interest, and is expected to close by the end of Q2 2026, while 2026 revenue and EBITDA guidance remain unchanged.
UCB's shares hit a record high after positive trial results for its drug Bimzelx, while MoonLake's stock plummeted following disappointing late-stage trial data for its drug sonelokimab, which showed inferior efficacy in treating hidradenitis suppurativa.
The FDA has approved UCB's Rystiggo, a treatment for generalized myasthenia gravis, making it the first drug to receive approval for both main subtypes of the rare autoimmune disease. UCB plans to make the under-the-skin treatment commercially available in the third quarter, following the recent approval of argenx's Vyvgart Hytrulo in subcutaneous form.